ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

ClinicalTrials.gov ID: NCT04014075

Public ClinicalTrials.gov record NCT04014075. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 5:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open-label, Single-arm Trial of Trastuzumab Deruxtecan (DS 8201a) in HER2-positive, Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-containing Regimen (DESTINY-Gastric02)

Study identification

NCT ID
NCT04014075
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Daiichi Sankyo
Industry
Enrollment
79 participants

Conditions and interventions

Interventions

  • Trastuzumab deruxtecan Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 25, 2019
Primary completion
Nov 7, 2021
Completion
Feb 12, 2024
Last update posted
Apr 2, 2025

2019 – 2024

United States locations

U.S. sites
20
U.S. states
11
U.S. cities
18
Facility City State ZIP Site status
City of Hope Medical Center Duarte California 91010
USC Norris Comprehensive Cancer Center Hospital Los Angeles California 90033
Pacific Cancer Care Monterey California 93940
UCLA Health Santa Monica California 90404
Hartford Hospital Hartford Connecticut 06102
MidState Medical Center Meriden Connecticut 06451
The Hospital of Central Connecticut New Britain Connecticut 06052
Smilow Cancer Hospital at Yale-New Haven New Haven Connecticut 06511
Miami Cancer Institute, Baptist Health South Florida Miami Florida 33176
University of Chicago Medical Center UCMC Duchossois Center for Advanced Medicine DCAM Chicago Illinois 60637
Kansas University Cancer Center Kansas City Kansas 66205
Massachusetts General Hospital (MGH) Boston Massachusetts 02114
Beth Israel Deaconess Medical Center (BIDMC) Boston Massachusetts 02215
Dana-Farber Cancer Institute Boston Massachusetts 02215
Alvin J. Siteman Cancer Center Washington University St Louis Missouri 63110
Northwell Health Cancer Institute Lake Success New York 11042
Memorial Sloan Kettering Cancer Center New York New York 10065
Lehigh Valley Health Network Allentown Pennsylvania 18103
The University of Texas MD Anderson Cancer Center Houston Texas 77030
University of Washington/Seattle Cancer Care Alliance Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04014075, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 2, 2025 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04014075 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →